AcelRx Pharmaceuticals, Inc. News Releases http://ir.acelrx.com/ AcelRx Pharmaceuticals, Inc. News Releases en AcelRx announces the closing of a $25 million senior secured debt facility http://ir.acelrx.com/news-releases/news-release-details/acelrx-announces-closing-25-million-senior-secured-debt-facility REDWOOD CITY, Calif. , June 3, 2019 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced the closing of a $25 million senior Mon, 03 Jun 2019 07:00:00 -0400 AcelRx Pharmaceuticals, Inc. News Releases 11456 AcelRx Pharmaceuticals Reports First Quarter 2019 Financial Results http://ir.acelrx.com/news-releases/news-release-details/acelrx-pharmaceuticals-reports-first-quarter-2019-financial REDWOOD CITY, Calif. , May 8, 2019 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today reported its first quarter 2019 Wed, 08 May 2019 16:01:00 -0400 AcelRx Pharmaceuticals, Inc. News Releases 11426 AcelRx to announce first quarter 2019 results and provide an update on the company's business on Wednesday, May 8th, 2019 http://ir.acelrx.com/news-releases/news-release-details/acelrx-announce-first-quarter-2019-results-and-provide-update REDWOOD CITY, Calif. , April 25, 2019 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company, today announced that it will release first quarter financial results after market close on Wednesday, May 8th, 2019 . Thu, 25 Apr 2019 16:05:00 -0400 AcelRx Pharmaceuticals, Inc. News Releases 11406 AcelRx Pharmaceutical's pooled safety results for sufentanil sublingual tablets (DSUVIA) selected for presentation at 44th Annual Regional Anesthesiology & Acute Pain Medicine Meeting http://ir.acelrx.com/news-releases/news-release-details/acelrx-pharmaceuticals-pooled-safety-results-sufentanil REDWOOD CITY, Calif. , April 11, 2019 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced an abstract about the safety of Thu, 11 Apr 2019 16:37:00 -0400 AcelRx Pharmaceuticals, Inc. News Releases 11396 AcelRx Pharmaceuticals to Present at Oppenheimer & Co. Inc. 29th Annual Healthcare Conference http://ir.acelrx.com/news-releases/news-release-details/acelrx-pharmaceuticals-present-oppenheimer-co-inc-29th-annual REDWOOD CITY, Calif. , March 11, 2019 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the use in medically supervised settings, today announced that management will be Mon, 11 Mar 2019 16:01:00 -0400 AcelRx Pharmaceuticals, Inc. News Releases 11381 AcelRx Pharmaceuticals Announces Commercial Launch of DSUVIA and Reports Fourth Quarter and Full Year 2018 Financial Results http://ir.acelrx.com/news-releases/news-release-details/acelrx-pharmaceuticals-announces-commercial-launch-dsuvia-and - DSUVIA now available for use in certified medically supervised healthcare settings, with initial shipments to wholesalers completed in the second half of February 2019 - Executed contracts with Group Purchasing Organizations (GPOs) covering approximately 80% of commercial launch targets - Cash, Thu, 07 Mar 2019 16:01:00 -0500 AcelRx Pharmaceuticals, Inc. News Releases 11361 AcelRx to announce fourth quarter 2018 results and provide a corporate update on Thursday, March 7th, 2019 http://ir.acelrx.com/news-releases/news-release-details/acelrx-announce-fourth-quarter-2018-results-and-provide REDWOOD CITY, Calif. , Feb. 22, 2019 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company, today announced that it will release fourth quarter and annual financial results after market close on Thursday, March 7th, 2019 . Fri, 22 Feb 2019 09:25:00 -0500 AcelRx Pharmaceuticals, Inc. News Releases 11326 AcelRx Pharmaceutical's sufentanil sublingual tablet (DSUVIA) to be highlighted during a presentation at the Boswick Burn and Wound Symposium http://ir.acelrx.com/news-releases/news-release-details/acelrx-pharmaceuticals-sufentanil-sublingual-tablet-dsuvia-be REDWOOD CITY, Calif. , Jan. 31, 2019 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced a presentation about DSUVIA™ and Thu, 31 Jan 2019 07:00:00 -0500 AcelRx Pharmaceuticals, Inc. News Releases 11286 AcelRx Pharmaceuticals announces publication analyzing pooled data on sufentanil sublingual tablets for short-term treatment of moderate-to-severe acute pain http://ir.acelrx.com/news-releases/news-release-details/acelrx-pharmaceuticals-announces-publication-analyzing-pooled - Over 800 patients from AcelRx studies supporting DSUVIA™ approval were included in the pooled safety analysis - Initial dosing of 30 mcg sufentanil sublingual tablet calculated as dose-equivalent to 5 mg of IV morphine REDWOOD CITY, Calif. , Jan. 7, 2019 /PRNewswire/ --  AcelRx Pharmaceuticals, Mon, 07 Jan 2019 08:30:00 -0500 AcelRx Pharmaceuticals, Inc. News Releases 11271 AcelRx Pharmaceuticals added to the NASDAQ Biotechnology Index (NBI) http://ir.acelrx.com/news-releases/news-release-details/acelrx-pharmaceuticals-added-nasdaq-biotechnology-index-nbi REDWOOD CITY, Calif. , Dec. 18, 2018 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced it has been selected for Tue, 18 Dec 2018 07:00:00 -0500 AcelRx Pharmaceuticals, Inc. News Releases 11266